WO2006053485A1 - Vaccin genique contre le bacille mycobacterium tuberculosis obtenu a partir d’un gene chimere et procede de preparation dudit vaccin - Google Patents
Vaccin genique contre le bacille mycobacterium tuberculosis obtenu a partir d’un gene chimere et procede de preparation dudit vaccin Download PDFInfo
- Publication number
- WO2006053485A1 WO2006053485A1 PCT/CN2005/001914 CN2005001914W WO2006053485A1 WO 2006053485 A1 WO2006053485 A1 WO 2006053485A1 CN 2005001914 W CN2005001914 W CN 2005001914W WO 2006053485 A1 WO2006053485 A1 WO 2006053485A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- chimeric
- mycobacterium tuberculosis
- ag85a
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Definitions
- the present invention relates to a novel vaccine technology in the field of biomedicine, and specifically relates to a Mycobacterium tuberculosis chimeric gene vaccine which is developed by the gene chimeric technology and represents the third vaccine revolution. Background technique
- BCG has no immunoprotective effect on adult tuberculosis, coupled with the increasing isolation rate of multi-antibiotic tuberculosis strains and the increase in cases of AIDS complicated with tuberculosis, tuberculosis has become the most dangerous infectious disease threatening human life and health.
- Finding a new vaccine that is better than BCG vaccine has become a hotspot and a hot topic in the world for research and development of new vaccines against adult tuberculosis.
- the DNA vaccine also known as genetic vaccine
- a DNA vaccine was immunized with a "naked engineering plasmid" produced by E. coli.
- a plasmid also referred to as a vector or plasmid vector or vector plasmid, is a circular supercoiled DNA that can replicate and express independently of the chromosome in E. coli cells.
- a DNA vaccine is a gene that genetically engineeres an E. coli plasmid into which a preferred antigenic protein encoding a pathogen is inserted, preferably an immunopotentiating cytokine, such as an interleukin 12 (IL-12), a cell colony stimulating factor (GM).
- IL-12 interleukin 12
- GM cell colony stimulating factor
- the plasmid can express the encoded antigen in the relevant cells, particularly antigen-processing cells (APC), and induce the body to produce body fluids and cells.
- APC antigen-processing cells
- the well-prepared plasmid DNA currently developed for different types of pathogens can be used in eukaryotic expression vector JW4303, or pcDNA3.1, or pVAXl series, but mainly using the FDA recommended anti-Kanamycin antibiotic for human body.
- the E. coli plasmid pVAXl was transformed.
- the eukaryotic expression vector plasmid is transformed into Escherichia coli (referred to as an engineered strain at this time), and under optimized conditions, the engineered bacteria are cultured to promote the proliferation of the bacteria, and the plasmid in the bacteria is copied into multiple copies.
- the bacteria are collected, and the bacteria are lysed under appropriate conditions to release the plasmid; after collection, the impurities are removed, and the plasmid is purified, and can be used as a DNA vaccine or a genetic vaccine for vaccination.
- a successful example is the coding gene for HIV V3 encoded in the gene encoding hepatitis B surface antigen (HbsAg).
- the V3 epitope of the HIV coat protein antigen is a very important protective antigen to determine sputum, but due to its small molecular weight, it is difficult to induce a strong immune response.
- the gene encoding HIV V3 was chimeric in a gene encoding hepatitis B surface antigen (HbsAg), and as a result, this chimeric gene was able to induce a humoral and cellular immune response specific against HIV V3 (Bryder, "Imoroved immunogenicity Of HIV-1 epitopes in HbsAg chimeric DNA vaccine plasmids by structural mutations of HbsAg", DNA and Cell Biology, 18(3): 219-225, 1999).
- HbsAg hepatitis B surface antigen
- the protein antigen of the Mycobacterium tuberculosis protective antigen ESAT6 gene encoding the immunogenicity and the immunogenicity of the Mycobacterium tuberculosis protective antigen Ag85b gene have been fused together.
- the chimeric approach has the potential to chimeric a small gene in the middle of a large gene, enhancing the immunogenicity of the weak gene without affecting the immunological activity of the large gene expression product.
- no studies have been reported on the use of chimeric gene technology in the construction of the Mycobacterium tuberculosis gene vaccine.
- the present inventors have surprisingly discovered that the novel E. coli mosaic is produced by fitting the ESAT6 gene encoding the minimal M. tuberculosis protective antigen into the gene encoding the most immunoprotective Ag85a antigen by gene chimeric technology.
- the genetic vaccine has shown superior immunity to single-gene vaccines in animal experiments, and its induced anti-ESAT6 antibody and anti-Ag85a antibody are higher than those produced by single-gene vaccine or two-gene fusion vaccine, and thus may be used in actual vaccines. .
- the chimeric Mycobacterium tuberculosis gene vaccine of the present invention comprises the Mycobacterium tuberculosis structural protein Ag85a gene shown in SEQ ID NO: 1 and the Mycobacterium tuberculosis ESAT6 gene shown in SEQ ID NO: 2, wherein the ESAT6 gene is chimeric in the sequence of the Ag85a gene.
- the Ag85a gene is ligated into a eukaryotic expression vector.
- the preparation method of the chimeric Mycobacterium tuberculosis gene vaccine of the present invention comprises the following steps:
- the chimeric gene vaccine HG856 was obtained by ligating the digested product of the step (4) with a ligase.
- the present inventors searched for the epitope of the Mycobacterium tuberculosis structural protein Ag85a gene by Epitope Informatics of the computer software service company Intenet-based applied bioinformatics company, and found that the epitope was mainly concentrated at the amino terminus and the carboxy terminus of Ag85a (D'Souza). "Mapping of murine Thl helper T-cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis", Infection and Immunity, 7(l): 483-493, 2003).
- the sequences recognized by the following restriction enzymes can be found, which are the Kpn l recognition sequences at positions 245-250, respectively; and the Pst l recognition sequences at positions 325-330. ; and the Acc I identification sequence at positions 430-435.
- the restriction endonuclease site of the Mycobacterium tuberculosis Ag85a gene (SEQ ID NO: 1), the restriction endonuclease Kpn I recognition sequence at position 245-250 (GGTACC), and the restriction of the 325-330 (CTGCAG) position Endonuclease Pst l recognition sequence and/or restriction endonuclease Acc I recognition sequence at position 430-435 (GTCTAC), inserting other smaller gene sequences, such as the gene ESAT6 encoding the Mycobacterium tuberculosis protective antigen (sequence 2), can be constructed into a chimeric tuberculosis gene vaccine.
- the present inventors designed primers a and primers b with restriction endonucleases Nhe ⁇ (GCTAGC) and BamH I (GGATCC ) recognition sites, and amplified the Ag85a parental gene from the chromosomal DNA of Mycobacterium tuberculosis by PCR.
- the endonucleases Nhe I and BamH I digested the Ag85a gene and the eukaryotic expression vector, respectively, and then ligated the digested products of both to construct a plasmid containing the parent gene HG85.
- the present inventors also designed primers carrying a Kpn I restriction endonuclease recognition sequence, a Pst I restriction endonuclease recognition sequence or an Acc I restriction endonuclease recognition sequence at the 5' end, respectively, for the ESAT6 minigene PCR amplification.
- Eukaryotic expression vector containing the Ag85a parental gene and primers carrying the Kpn I restriction endonuclease recognition sequence at the 5' end were separately digested with Kpn I restriction enzyme, and then the ESAT6 minigene PCR amplification product was obtained.
- the digested products were ligated with ligase, and the correct orientation was selected to construct a tuberculosis chimeric gene vaccine HG856K (HG856-1) plasmid.
- the eukaryotic expression vector containing the Ag85a parent gene and the ESAT6 minigene PCR amplification product obtained by the primer carrying the Acc I restriction endonuclease recognition sequence at the 5' end were separately digested with Acc I restriction enzyme, and then both were The digestive products were ligated with ligase, and the correct orientation was selected to construct a Mycobacterium tuberculosis chimeric gene vaccine HG856A (HG856-2) plasmid.
- the eukaryotic expression vector containing the Ag85a parental gene and the ESAT6 minigene PCR amplification product obtained by using the primer of the Pst I restriction endonuclease recognition sequence at the 5' end were separately digested with Pst I restriction endonuclease, and then both were The digested products were ligated with ligase, and the correct orientation was selected to construct a Mycobacterium tuberculosis chimeric gene vaccine HG856P (HG856-3) plasmid.
- the chimeric gene vaccine for preventing tuberculosis of the present invention is a relatively small tuberculosis bacillus.
- the ESAT6 gene is inserted into a suitable site of the relatively large M. tuberculosis Ag85a parental gene.
- the chimeric Mycobacterium tuberculosis gene vaccines HG856K and HG856A plasmids were constructed by inserting the ESAT6 gene into the Kpn I recognition sequence site at positions 245-250 of the Ag85a parental gene and the Acc I recognition sequence site at positions 430-435. Immunogenicity is preferred.
- the present invention employs a gene chimeric technique to encode the ESAT6 gene encoding the minimal M. tuberculosis protective antigen.
- the novel Mycobacterium tuberculosis chimeric gene vaccine which is chimeric into the gene encoding the most immunoprotective A g 85a antigen, shows an immune effect superior to that of a single gene vaccine in animal experiments, which induces the production of anti-ESAT6 and Anti-Ag85a antibodies are produced more than single gene vaccines or two gene fusion vaccines.
- Figure 1 shows the difference between a fusion gene and a chimeric gene.
- Figure 2 is a construction diagram of the eukaryotic expression vector HG85-pVAX1 containing the Mycobacterium tuberculosis Ag85a parent gene.
- Fig. 3 is a view showing the construction of a Mycobacterium tuberculosis chimeric gene vaccine HG856 of the present invention.
- Figure 4 shows the fusion protein of Mycobacterium tuberculosis Ag85a and ESAT6 expressed in vitro by the chimeric gene vaccine HG856.
- Figure 5 shows the results of immunoblotting of the Ag85a protein expressed by the chimeric gene vaccine HG856 in vitro.
- Figure 6 shows the changes in the levels of Mycobacterium tuberculosis Ag85a-specific antibodies in the serum of mice after booster immunization.
- Figure 7 shows the changes in the levels of Mycobacterium tuberculosis ESAT6-specific antibodies in the serum of mice after booster immunization.
- Figure 8 shows changes in the levels of Mycobacterium tuberculosis Ag85a-specific antibodies in monkey serum after booster immunization.
- Figure 9 shows changes in the levels of Mycobacterium tuberculosis ESAT6-specific antibodies in monkey serum following booster immunization.
- Primer a is identical to the 5' end of the Ag85a gene coding sequence and is complementary to the nucleotide sequence 2 to 22 encoding the structural protein Ag85a gene (see Sequence 1). At its 5th end, it contains a Nhe I (GCTAGC) digestion recognition sequence.
- GCTAGC Nhe I
- the bow b is identical to the 3' end of the Ag85a gene coding sequence and is complementary to the nucleotide sequences 869 to 885 of the Ag85a gene. It contains a BamH I (GGATCC) digestion recognition sequence at its 5' end.
- the Mycobacterium tuberculosis standard strain H37RV chromosomal DNA was used as a template, and high-fidelity pf DNA polymerase was used for PCR reaction to amplify Mycobacterium tuberculosis Ag85a gene.
- the amount of template, the amount of primers, the amount of enzyme, and the buffer used were all carried out according to the conventional method of genetic engineering molecular cloning technology (see J. Sambrook, DW Russell, Huang Peitang, etc.) "Molecular Cloning Experimental Guide", third Edition, 597-632 pages, August 2002, Science Press, Beijing).
- the concentrations of the four dNTPs were 20 w M and the concentration of Mg 2+ was 1.5 mM.
- Nhe I (GCTAGC) and BamH I (GGATCC) restriction endonuclease sites were introduced into primer a and primer b in Example 1, respectively, and the Mycobacterium tuberculosis Ag85a gene fragment obtained by PCR technique and the eukaryotic expression vector pVAXl were obtained.
- Plasmid purchased from Invitrogen, Carlsbad, CA, USA
- 10 units of Nhe I and BamH I restriction enzymes 1 ⁇ g each, add 10 units of Nhe I and BamH I restriction enzymes, and mix in 50 ⁇ l of reaction buffer (according to each enzyme kit) Instructions for use in buffer), 37 ⁇ digestion for 1 hour, by conventional agarose gel electrophoresis separation and gel DNA recovery method (according to J.
- the engineered bacteria were cultured in a medium containing kanamycin, collected by centrifugation, and the plasmid was extracted by alkaline lysis, and digested with two different enzymes, Nhe l and BamH I, and the products were subjected to agar electrophoresis to verify the correct positive clone. , select the correct plasmid containing the Mycobacterium tuberculosis gene HG85 for subsequent chimeric manipulation.
- DNA ligation using Promega's kit, follow the instructions: Mix 1 ⁇ l of T4 ligase, 1 ⁇ l of 10 X buffer, 7 ⁇ l of Ag85a DNA fragment, 1 ⁇ l of pVAX1 plasmid fragment, and mix Connected overnight at 14 °C. (See J. Sambrook, D. W. Russell, Huang Peitang, et al., "Guidelines for Molecular Cloning," Third Edition, pp. 85-86, August 2002, Science Press, Beijing).
- the ligated pVAX1 plasmid (gene recombinant HG85 cloning plasmid) containing the Ag85a gene was added to competent cells of Escherichia coli DG1 or DH5a, and the cells were transformed by reaction at 37 ° C for 1 hour. 200 ⁇ l of the agar medium plate containing kanamycin was taken out, and the bacteria were spread and cultured for 37-18 hours at 37 °C.
- the pVAX1 vector plasmid contains an anti-kanamycin gene, and thus E. coli successfully transformed with the recombinant HG85 cloning vector plasmid can grow into a colony on this medium. Monoclonal colonies were selected and inoculated into 3 ml of the culture medium containing kanamycin, and cultured at 37 ° C, shaking at 200 rpm for about 14 hours. Remove 1 ml of the bacterial solution at 12000 rpm.
- the lignin c is identical to the 5' end of the ESAT6 gene coding sequence and is complementary to the nucleotide sequences 1 to 18 of the ESAT6 gene, and contains a Kpn l restriction recognition sequence at the 5th end.
- Primer d is identical to the 3' end of the ESAT6 gene coding sequence and is complementary to the 268th to 285th nucleotide sequences of the ESAT6 gene, and also contains a Kpn I restriction recognition sequence at the 5' end.
- the Mycobacterium tuberculosis standard strain H37RV chromosomal DNA was used as a template, and a high-fidelity pfu DNA polymerase was used for PCR reaction to amplify the Mycobacterium tuberculosis ESAT6 gene.
- the amount of template, the amount of primers, the amount of enzyme, and the buffer used were all carried out according to the conventional methods of genetic engineering molecular cloning techniques (see J. Sambrook, DW Russell, Huang Peitang, etc.) Guide to Molecular Cloning, Third Edition, 85-86 pages, August 2002, Science Press, Beijing).
- the concentrations of the four dNTPs were 20 ⁇ and the Mg 2+ concentration was 1.5 mM; the denaturation, annealing, and extension temperatures were 94 ° C, 55 ° C, and 72 ° C, respectively, and the time was 1 minute.
- the ESAT6 gene DNA sequence was obtained.
- the HG85-pVAX1 plasmid containing the Mycobacterium tuberculosis gene Ag85a obtained in Example 2 was digested with Kpn I restriction enzyme to obtain a fragment thereof, and the DNA sequence fragment of the Mycobacterium tuberculosis ESAT6 gene having the Kpn I digestion recognition sequence obtained above was obtained.
- a method substantially similar to that of Example 2 agarose gel electrophoresis, DNA fragment recovery in gel and DNA ligation
- two fragments were ligated with T4 ligase, and the ESAT6 gene DNA sequence was inserted into the Mycobacterium tuberculosis A g 85a gene.
- the sequence of the 249 Kpn I enzyme recognition site was substantially similar to that of Example 2 (agarose gel electrophoresis, DNA fragment recovery in gel and DNA ligation).
- the recombinant clone was transformed into competent E. coli as described above, and plated with kanamycin agar. After selecting 3-5 positive colonies for a small amount of bacteria, the plasmid DNA was extracted as a template; according to the Ag85a gene, it was close to ESAT6. The sequence of the 5'-end junction of the gene, a pair of primers were designed and PCR amplified, and the Ag85a gene and the ESAT6 gene junction of the amplified product were sequenced, and the insertion direction was selected to construct the Mycobacterium tuberculosis Ag85a and ESAT6 genes. A chimeric genetic vaccine HG856K plasmid.
- the bower I is 5' to the ESAT6 gene coding sequence and is complementary to the 1st to 18th nucleotide sequences of the ESAT6 gene. At its 5th end, it contains an encutase recognition sequence of Acc I.
- the bower i is identical to the 3 of the ESAT6 gene coding sequence and is complementary to the nucleotide sequence 268 to 285 of the ESAT6 gene. It also contains an En 1 recognition sequence for Acc I at its 5' end.
- primer e and primer f using the chromosomal DNA of Mycobacterium tuberculosis standard strain H37RV as a template, PCR was carried out with high-fidelity pfti DNA polymerase.
- the amount of template, the amount of primers, the amount of enzyme, and the buffer used were all cloned by genetic engineering. Conventional methods are carried out (see J. Sambrook, DW Russell, Huang Peitang et al., "Molecular Cloning Experimental Guide", Third Edition, pp. 85-86, August 2002, Science Press, Beijing).
- the concentrations of the four dNTPs were 20 ⁇ , the Mg 2+ concentration was 1.5 mM, and the denaturation, annealing, and extension temperatures were 94 ° C, 55 ° C, and 72 ° C, respectively, and the time was 1 minute.
- Get ESAT6 base cause
- the HG85-pVAX1 plasmid containing the Mycobacterium tuberculosis gene Ag85a obtained in Example 2 was digested with Acc I restriction enzyme to obtain a fragment thereof, and the DNA of the Mycobacterium tuberculosis ESAT6 gene having the Acc I endonuclease recognition sequence obtained above was obtained.
- Sequence fragment according to a method substantially similar to that of Example 2 (agarose gel electrophoresis, DNA fragment recovery in gel and DNA ligation), the two fragments were ligated with T4 ligase, and the ESAT6 gene DNA sequence was inserted into the Mycobacterium tuberculosis Ag85a gene sequence.
- the recombinant clone was transformed into competent E. coli as described above, and plated with kanamycin agar. After selecting 3-5 positive colonies, a small amount of bacteria was added, and then extracted. Using plasmid DNA as a template; according to the sequence of the Ag85a gene near the 5'-end junction of the ESAT6 gene, a pair of primers were designed and PCR amplified, and the Ag85a gene and ESAT6 gene junction of the amplified product were sequenced, and the insertion direction was selected correctly.
- the gene vaccine HG856A plasmid containing the Mycobacterium tuberculosis Ag85a and ESAT6 genes was constructed.
- Primer g is identical to the 5' end of the ESAT6 gene coding sequence and is complementary to the 1st to 18th nucleotide sequences of the ESAT6 gene. It contains a Pst I restriction recognition sequence at its 5' end.
- the bower I is identical to the 3' end of the ESAT6 gene coding sequence and is complementary to the 268th to 285th nucleotide sequences of the ESAT6 gene. It also contains a Pst I restriction recognition sequence at its 5' end.
- the sequence of the Pst I restriction site was designed in the primer, and the ESAT6 gene PCR product containing the restriction site was digested with Pst I restriction enzyme, and then inserted.
- the recombinant clone was transformed into competent E.
- the T N T in vitro transcription and translation system kit (Promega, Madison, WI, USA) was used to verify the expression of the chimeric Mycobacterium tuberculosis gene HG856 in vitro. Contains 0.25 ⁇ g of chimeric Mycobacterium tuberculosis gene HG856 plasmid DNA and 9 ⁇ l of T N T T7 rapid reaction stock solution in a 12.5 ⁇ l reaction system according to the experimental procedure described in the Promega instructions of the United States, with 400 ⁇ per ml Ci [S 35 ] labeled methionine was mixed and incubated at 30 ° C for 90 minutes.
- Lanes 1 to 5 are proteins expressed by five clones of the Mycobacterium tuberculosis gene to be screened.
- the molecular weight of the cloned protein expressed in lane 4 was approximately 42 kDa, as compared to the 29 kDa and 44 kDa bands of standard protein molecular weight.
- the molecular weight of Mycobacterium tuberculosis Ag85a protein antigen is about 32kDa; while the molecular weight of Mycobacterium tuberculosis ESAT6 protein antigen is about 10kDa, and the sum of the two is about 42kDa.
- lane 4 is the product expressed by the chimeric tuberculosis gene HG856.
- Experimental Example 2 Western blotting experiment The 0.25 ⁇ g of Mycobacterium tuberculosis protein antigen Ag85a and the molecular weight marker protein were subjected to SDS-polyacrylamide gel vertical electrophoresis, and then the protein was transferred to a nitrocellulose membrane by a method of 100 V electrotransfer for 1.5 hours.
- the first column is the molecular weight marker protein; the second column is the Ag85a single gene vaccine; the third column is the HG856A chimeric gene (inserted at the 432-position of the Ag85a gene); the fourth column is the HG856K chimeric gene ( Inserted into the 249th Kpnl cleavage site of the Ag85a gene).
- SPF Specific Pathogen Free animal house words provided by the Animal Center of Shanghai Second Military Medical University.
- protein After immunization with three nucleic acid vaccines, protein is used for final booster immunization.
- mice 40 female BALB/C mice were randomly divided into 8 groups, 5 in each group: group 1-2 (ESAT6 single gene vaccine), group 3-4 (Ag85a single gene vaccine), group 5-6 (HG856A chimeric gene vaccine), Groups 7-8 (HG856K chimeric gene vaccine).
- the single array was the intramuscular injection group, which was injected 100 ug/time into the tibialis anterior muscle respectively.
- the double array was intramuscularly injected and then transfected into the anterior tibialis anterior muscle for 10 yg/time, and immunized once every two weeks for 3 times. . On the 10th day after the last immunization, the serum collected and separated from the tail vein was measured for ELISA by ELISA.
- the gene immunization has produced a specific immune response, that is, 8-12 days after the third gene vaccine immunization, the corresponding Mycobacterium tuberculosis protein antigen is used for intraperitoneal vaccination to boost the immunization, 50 g/mouse.
- the animals were anesthetized and sacrificed to harvest whole blood. The centrifuged serum was stored at - 20 °C.
- Protein protein M white matter protein before strengthening After strengthening, strengthening before strengthening
- the GMT of the non-immunized control group was 9.7.
- Intraperitoneal injection of 50 ug of Mycobacterium tuberculosis Ag85a protein antigen was used as booster.
- La is the Ag85a single gene vaccine before inoculation, lb is after Ag85a single gene vaccine;
- Ha is vaccinated with HG856A before vaccination for HG856A;
- Illb was vaccinated with HG856K.
- the electro-transfection method Ag85a single-gene vaccination is only 1/10 of the amount of intramuscular injection, the effect is comparable, or even slightly better; Ag85a single gene or chimeric gene
- the effect of the vaccine was not significantly different.
- the chimeric gene vaccine was not as effective as single-gene vaccine when it was injected intramuscularly; however, the electro-transfected chimeric gene vaccine was superior to the single-gene vaccine and was superior to simple intramuscular injection. It is suggested that the chimeric gene vaccine can be used as a basic vaccination for electroporation, and further enhanced by protein vaccine has a good application prospect.
- Table 2 ESAT6-specific antibody levels of Mycobacterium tuberculosis in mouse serum after vaccination with tuberculosis gene vaccine and corresponding protein vaccine
- ESAT6 strengthens ESAT6+Ag85a strengthens before strengthening strengthens before strengthening before strengthening strengthening before strengthening
- the ESAT6 antigen is a weak antigen, which is much weaker than the Ag85a antigen. It is difficult to induce a strong immune response after vaccination, but its immunogenicity is enhanced after chimerization in Ag85a.
- the ESAT6 single-gene vaccination is only 1/10 of the amount of intramuscular injection by electrotransfection, and the effect is comparable; the protein vaccine enhances the pre-ESAT6 single gene or chimeric gene vaccine. The effect is similar.
- the ESAT6 single gene vaccine was not effective in muscle or electrotransfection alone; the chimeric gene HG856A vaccine was slightly better than the ESAT6 single gene vaccine and the chimeric gene HG856K vaccine when it was injected intramuscularly; The two chimeric genes HG856A and HG856K vaccines were significantly better than single-gene vaccines, and were much better than simple intramuscular injections. Especially when enhanced with protein antigen, whether it is enhanced with ESAT6 antigen or ESAT6 and Ag85a, it can significantly enhance the immunogenicity of the weak antigen ESAT6.
- the chimeric gene vaccine can be used as a basic vaccination for electroporation, and the use of protein vaccine enhancement has a good application prospect.
- protein vaccine enhancement has a good application prospect.
- the chimeric tuberculosis gene vaccine described herein is suitable for basal immunization.
- the results of this experimental example show that: The novel chimeric tuberculosis gene vaccine can simultaneously induce specific antibodies against Mycobacterium tuberculosis Ag85a and ESAT6 in mice, and the effect is better than Ag85a single gene vaccine and ESAT6 single gene vaccine.
- Basic immunization Experimental Example 4 Mycobacterium tuberculosis chimeric gene HG856 plasmid-inoculated rhesus monkey (Rhesus monkey) induced serum-specific antibody immune response (ELISA method) Materials and methods -
- Group 1 ESAT6 single gene vaccine
- Group 2 ESAT6 inserted into the Ag85a249 site of the chimeric gene vaccine HG856K
- Group 3 ESAT6 inserted at the Ag85a432 site of the chimeric gene vaccine HG856A.
- the monkeys were anesthetized with ketamine, they were intramuscularly injected into the thighs and arms of the muscles at 500 g/time.
- the corresponding Mycobacterium tuberculosis protein antigen was used for muscle inoculation to boost the immunization, 500 ⁇ g/head.
- the animals were anesthetized and sacrificed to harvest whole blood. The centrifuged serum was stored at -20 °C.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100843761A CN100354004C (zh) | 2004-11-19 | 2004-11-19 | 结核杆菌嵌合基因疫苗及其制备方法 |
CN200410084376.1 | 2004-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006053485A1 true WO2006053485A1 (fr) | 2006-05-26 |
Family
ID=36079561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2005/001914 WO2006053485A1 (fr) | 2004-11-19 | 2005-11-14 | Vaccin genique contre le bacille mycobacterium tuberculosis obtenu a partir d’un gene chimere et procede de preparation dudit vaccin |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN100354004C (zh) |
WO (1) | WO2006053485A1 (zh) |
ZA (1) | ZA200704459B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010010577A1 (en) * | 2008-07-25 | 2010-01-28 | Department Of Biotechnology | Constructing a dna chimera for vaccine development against leishmaniasis and tuberculosis |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101088559B (zh) * | 2006-06-12 | 2011-12-07 | 上海欣安基因免疫与疫苗研究开发有限公司 | 一种多表位结核基因疫苗及其制备方法 |
CN101376891B (zh) * | 2007-08-27 | 2012-05-23 | 上海生物制品研究所有限责任公司 | 新型结核病疫苗的制备及其应用 |
CN101376025B (zh) * | 2007-08-29 | 2012-05-23 | 中国人民解放军总医院第二附属医院 | 用于制备治疗耐药结核病的结核杆菌基因疫苗 |
CN101912605A (zh) * | 2010-04-23 | 2010-12-15 | 上海市公共卫生临床中心 | 增强型嵌合基因重组卡介苗及其制备方法 |
CN102268446B (zh) * | 2010-06-03 | 2013-01-02 | 上海海规生物科技有限公司 | 结核杆菌Ag85ab嵌合基因疫苗、其制备方法及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024577A1 (en) * | 1997-11-10 | 1999-05-20 | Statens Serum Institut | NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS) |
WO2000047227A2 (en) * | 1999-02-09 | 2000-08-17 | Powderject Vaccines, Inc. | Mycobacterium tuberculosis, immunization |
CN1467221A (zh) * | 2002-07-14 | 2004-01-14 | 虹 王 | 结核杆菌cfp-10、esat-6与cd40l融合疫苗的制备及应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001271963A1 (en) * | 2000-07-10 | 2002-01-21 | Colorado State University Research Foundation | Mid-life vaccine and methods for boosting anti-mycobacterial immunity |
CN100438907C (zh) * | 2003-05-09 | 2008-12-03 | 浙江省医学科学院 | 一种戊型肝炎病毒嵌合基因疫苗 |
-
2004
- 2004-11-19 CN CNB2004100843761A patent/CN100354004C/zh active Active
-
2005
- 2005-11-14 WO PCT/CN2005/001914 patent/WO2006053485A1/zh active Application Filing
-
2007
- 2007-05-30 ZA ZA200704459A patent/ZA200704459B/xx unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024577A1 (en) * | 1997-11-10 | 1999-05-20 | Statens Serum Institut | NUCLEIC ACID FRAGMENTS AND POLYPEPTIDE FRAGMENTS DERIVED FROM $i(M. TUBERCULOSIS) |
WO2000047227A2 (en) * | 1999-02-09 | 2000-08-17 | Powderject Vaccines, Inc. | Mycobacterium tuberculosis, immunization |
CN1467221A (zh) * | 2002-07-14 | 2004-01-14 | 虹 王 | 结核杆菌cfp-10、esat-6与cd40l融合疫苗的制备及应用 |
Non-Patent Citations (2)
Title |
---|
KAMATH ARUN T ET AL: "DIfferential Protective Efficacy od DNA Vaccines Expressing Secreted Proteins of Mycobacterium tuberculosis.", INFECTION AND IMMUNITY., vol. 67, no. 4, April 1999 (1999-04-01), pages 1702 - 1707 * |
XIE YONGEN ET AL: "Constructionthe fused expression vector of mycobacterium tuberculosis Ag85A and ESAT-6 antigens and its expression in E. coli.", CHINESE JOURNAL OF ZOONOSES., vol. 18, no. 2, 2002, pages 28 - 31 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010010577A1 (en) * | 2008-07-25 | 2010-01-28 | Department Of Biotechnology | Constructing a dna chimera for vaccine development against leishmaniasis and tuberculosis |
KR20110060865A (ko) * | 2008-07-25 | 2011-06-08 | 디파트먼트 오브 바이오테크놀러지 | 리슈마니아증 및 결핵에 대한 백신 개발을 위한 dna 키메라의 작제 |
KR101598876B1 (ko) | 2008-07-25 | 2016-03-02 | 디파트먼트 오브 바이오테크놀러지 | 리슈마니아증 및 결핵에 대한 백신 개발을 위한 dna 키메라의 작제 |
Also Published As
Publication number | Publication date |
---|---|
CN1736490A (zh) | 2006-02-22 |
ZA200704459B (en) | 2009-04-29 |
CN100354004C (zh) | 2007-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0013828B1 (en) | Recombinant DNA, hosts transformed with it and processes for the preparation of polypeptides | |
Gram et al. | Immunological analysis of a Lactococcus lactis-based DNA vaccine expressing HIV gp120 | |
CA2035039C (en) | Recombinant poxvirus and streptococcal m protein vaccine | |
JPH07502646A (ja) | リポタンパク質の分泌シグナルをコード化するdnaを含む細菌発現ベクター | |
JP2001514000A5 (zh) | ||
JPH04506297A (ja) | ベクター媒介ゲノム挿入及びbcgにおけるdnaの発現 | |
WO2006053485A1 (fr) | Vaccin genique contre le bacille mycobacterium tuberculosis obtenu a partir d’un gene chimere et procede de preparation dudit vaccin | |
US20060140971A1 (en) | Cell surface expression vector of sars virus antigen and microorganisms transformed thereby | |
CN113461788A (zh) | 猫冠状病毒重组抗原、其基因工程亚单位疫苗及应用 | |
JP2003525619A (ja) | ウイルスコートタンパク質融合体としての植物における外来ポリペプチドの産生 | |
WO2011150745A1 (zh) | 结核杆菌ag85ab嵌合基因疫苗、其制备方法及应用 | |
CN111548395A (zh) | 一种口蹄疫病毒二价多表位重组病毒样颗粒及其应用 | |
JP6629975B2 (ja) | ブタシルコウイルス2型キャプシドタンパク質の調製方法及びそれを含む医薬組成物 | |
CN112399854A (zh) | 预防或治疗严重发热伴血小板减少综合征(sfts)病毒性感染所致疾病的疫苗组合物 | |
JPH07504082A (ja) | M.Paratuberculosisのプロモーター及び免疫原性配列の発現のためのその使用 | |
CN111850003A (zh) | 一种重组表达的多杀性巴氏杆菌硫胺素周质结合蛋白及应用 | |
WO2007104263A1 (zh) | 一种乙型肝炎病毒疫苗增效蛋白及其基因 | |
US20110150932A1 (en) | Constructing a DNA Chimera for Vaccine Development Against Leishmaniasis and Tuberculosis | |
CN116497049B (zh) | 一种表达犬疱疹病毒gD糖基化蛋白的重组菌及其应用 | |
CN111773384B (zh) | 布鲁氏菌病和口蹄疫二联疫苗及制备方法和应用 | |
EP1678301B1 (en) | Inducible bacterial expression system utilising sspa promoter from salmonella | |
US9963487B2 (en) | Production of polypeptides relevant to human and animal health using Yarrowia lipolytica | |
CN117866060A (zh) | 一种缺失高变区结构域的细菌鞭毛蛋白及其制备方法和应用 | |
JP2023518734A (ja) | インビトロトランスクリプトmrna及びこれを含有する薬学組成物 | |
CN117838890A (zh) | 一种c型副鸡禽杆菌亚单位疫苗及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 3388/DELNP/2007 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69/1) EPC |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05808240 Country of ref document: EP Kind code of ref document: A1 |